Hypertension trials recruiting in Oklahoma

All Hypertension trials nationally

Cities in Oklahoma

Recruiting trials in Oklahoma

• A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
  NCT07214376 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 85 Years · Sex: All (male and female) · Oklahoma: Tulsa
• A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
  NCT06822738 · Phase: Phase 3 · Ages: 45 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
  NCT06059638 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
  NCT06388421 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City, Tulsa
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Edmond, Oklahoma City
• Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
  NCT07090161 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Oklahoma: Norman, Oklahoma City
• Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
  NCT06911632 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
  NCT06274801 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Oklahoma: Oklahoma City
• Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
  NCT04278404 · Phase: Not specified · Ages: 0 Years to 20 Years · Sex: All (male and female) · Oklahoma: Oklahoma City
• Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
  NCT07075718 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
  NCT06559891 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years to 75 Years · Sex: All (male and female) · Oklahoma: Bartlesville
• Travoprost Intraocular Implant + iStent Infinite
  NCT06066645 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
  NCT06526195 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City, Tulsa
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
  NCT07181109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Edmond, Moore, Norman, Oklahoma City